Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 5/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14402898 | 0.81 | RAF1 (0.48) | RAF1MAPK14FLT3RIPK2RAB9A | |
| SCHEMBL668678 | 0.80 | FLT3 (0.73) | RAF1MAPK14FLT3RIPK2RAB9A | |
| SCHEMBL5575753 | 0.73 | MAPK14 (0.49) | RAF1MAPK14FLT3RIPK2RAB9A | |
| SCHEMBL16870271 | 0.72 | MAPK14 (0.55) | MAPK14RAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL667588 | 0.72 | RAF1 (0.72) | RAF1MAPK14FLT3RIPK2ALDH1A1 | |
| SCHEMBL5006752 | 0.71 | MAPK14 (0.57) | RAF1MAPK14FLT3RIPK2RAB9A | |
| SCHEMBL668089 | 0.70 | MEN1 (0.63) | RAF1MAPK14FLT3RIPK2RAB9A | |
| SCHEMBL5576199 | 0.69 | RAF1 (0.58) | RAF1MAPK14FLT3RIPK2RAB9A | |
| SCHEMBL13972318 | 0.69 | RAF1 (0.48) | RAF1MAPK14RIPK2ALDH1A1KMT2A | |
| SCHEMBL667543 | 0.68 | FLT3 (0.61) | RAF1MAPK14FLT3RIPK2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 127/4885FLT3 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.